riboflavin 5'-monophosphate | 34469-63-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 黄素核苷酸
• 英文名称: riboflavin 5'-monophosphate
• 英文别名: flavin mononucleotide；7,8-dimethyl-10-(O⁵-phosphono-pentitol-1-yl)-10H-benzo[g]pteridine-2,4-dione；Riboflavin-4':5'-monophosphat；Flavin-mononucleotid；Flavinmononucleotid；Riboflavine 5'-(dihydrogen phosphate)；[5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate
• CAS: 34469-63-1
• 化学式: C₁₇H₂₁N₄O₉P
• 分子量: 456.349
• InChiKey: FVTCRASFADXXNN-UHFFFAOYSA-N

物化性质

• 密度：
  1.83±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  202
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  riboflavin 5'-monophosphate 在 sodium hydroxide 、 三辛胺 作用下， 以 二甲基亚砜 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  黄素腺嘌呤二核苷酸作为均相比色免疫测定中的标记。

  摘要：

  DOI：

  10.1021/ac00227a021

文献信息

• NOVEL COCRYSTALLIZATION
  申请人：CHILDS Scott L.

  公开号：US20110257430A1

  公开（公告）日：2011-10-20

  The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.

  本公开涉及新型共晶体及新型共晶化方法。具体来说，公开包括包含活性物质的盐的共晶体，例如活性药物成分的氯化物盐。本公开还涉及制备共晶体的方法以及筛选固态相的方法。
• Riboswitches, methods for their use, and compositions for use with riboswitches
  申请人：Yale University

  公开号：EP2233494A1

  公开（公告）日：2010-09-29

  It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural "riboswitches" (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new nonimmunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.

  研究发现，某些天然 mRNA 可作为代谢物敏感的基因开关，其中的 RNA 可直接与一种小的有机分子结合。这种结合过程会改变 mRNA 的构象，从而通过各种不同的机制改变基因的表达。这些天然 "核糖开关 "的改良版（通过使用各种核酸工程策略创建）可用作由特定效应化合物控制的设计基因开关。这种激活核糖开关的效应化合物在本文中被称为触发分子。天然开关是抗生素和其他小分子疗法的目标。此外，核糖开关的结构允许使用天然开关的实际片段来构建新的非免疫原性基因控制元件，例如，可以将适配体（分子识别）结构域与其他非天然适配体进行交换（或以其他方式进行修改），从而使新的识别结构域能够使用用户定义的效应化合物进行基因调控。改变后的开关将成为治疗方案的一部分--开启、关闭或调节蛋白质合成。新构建的基因调控网络可应用于活体生物传感器、生物体代谢工程和先进的基因疗法等领域。
• Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound
  申请人：APTUIT (KANSAS CITY), LLC

  公开号：EP2292585A1

  公开（公告）日：2011-03-09

  The present invention relates to cocrystals of fluoxctinc hydrochloride and benzoic acid. Furthermore, methods are provided for producing the cocrystals.

  本发明涉及盐酸氟辛酸和苯甲酸的共晶体。此外，还提供了生产这种共晶体的方法。
• Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
  申请人：Universitäts-Kinderspital beider Basel

  公开号：EP2837390A1

  公开（公告）日：2015-02-18

  The present invention relates to a combined pharmaceutical preparation for use in a method for preventing or treating muscular dystrophy, comprising an activator of neuronal nitric oxide synthase, and a nitric oxide precursor, wherein said nitric oxide precursor is convertible by said nitric oxide synthase to nitric oxide

  本发明涉及一种用于预防或治疗肌肉萎缩症方法的组合药物制剂，包括神经元一氧化氮合酶激活剂和一氧化氮前体，其中所述一氧化氮前体可通过所述一氧化氮合酶转化为一氧化氮
• [EN] METHOD FOR PREPARING HIGH-PURITY RIBOFLAVIN SODIUM PHOSPHATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PHOSPHATE DE RIBOFLAVINE SODIQUE DE HAUTE PURETÉ<br/>[ZH] 高纯度核黄素磷酸钠的制备方法
  申请人：BONTAC BIO ENG SHENZHEN CO LTD

  公开号：WO2020056714A1

  公开（公告）日：2020-03-26

  一种高纯度核黄素磷酸钠的制备方法，该方法包括：调节pH值至5.0～7.0；控制溶液温度为20～40℃，并加入浓度为95％(ml/ml)的乙醇水溶液；降温至3～5℃，等待固体析出；过滤，滤饼经干燥处理后即得核黄素磷酸钠纯品。该方法适宜规模化从生物酶反应液或生物发酵液中分离纯化纯度在99％以上的核黄素磷酸钠产品。